- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07937982
Protocol CAUSE-05 RHINO (RHINO)
Respiratory Health & Infant Nasal 'Omics (RHINO) (CAUSE-05)
CAUSE-05/RHINO is an observational study designed to learn how babies' nasal cells grow and change during the first months of life. The study will enroll pregnant mothers in their third trimester and their infants upon delivery for a target population of 60 mother-baby pairs. Researchers will conduct up to 6 study visits and collect serial nasal samples through 4 months of age.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This is an observational, multicenter study designed to assess developmental changes in in vivo and in cultured neonatal nasal epithelial cells. The study will enroll pregnant females in their third trimester of pregnancy as well as their infants upon delivery. Approximately 60 mother-infant pairs will be observed from birth to age 4 months to describe early-life developmental patterns of nasal cell gene expression, including genes related to type-II (T2) inflammation, immune response, and epithelial barrier function.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: James E Gern, MD
- Numero di telefono: 608-263-6201
- Email: gern@medicine.wisc.edu
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Investigatore principale:
- Rajesh Kumar, MD
-
Contatto:
- Sarah Godley
- Numero di telefono: 312-227-6454
- Email: sgodley@luriechildrens.org
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University at St. Louis
-
Contatto:
- Gina Simpson
- Numero di telefono: 314-362-9139
- Email: simpsong@wustl.edu
-
Investigatore principale:
- Katherine Rivera-Spoljaric, MD
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229
- Cincinnati Children's Hospital Medical Center
-
Investigatore principale:
- Neeru Hershey, MD
-
Contatto:
- Molly Brausch-Bradner
- Numero di telefono: 513-803-0028
- Email: molly.brausch-bradner@cchmc.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Pregnant maternal participants from the pre-selected recruitment census tracts designated by the CAUSE program, aged 18 years or older, with a gestational age greater than or equal to 28 weeks, in addition to one offspring of each maternal participant.
Descrizione
Inclusion Criteria:
-
Able to understand and provide informed consent
-
Age 18 years or older
-
Currently pregnant, with:
- Gestational age ≥ 28 weeks as confirmed by participant self-report
- Intent to deliver at a participating clinical site labor and delivery (L&D) center
-
Agrees to enroll infant into the study at birth
-
In the case of multiple gestation, agrees to enroll only one infant who will be randomly selected
-
Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-05 (RHINO) Manual of Procedures (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion.
Exclusion Criteria:
- Inability or unwillingness to give written informed consent or comply with study protocol
- Insufficient proficiency in English or Spanish to provide informed consent and complete study procedures
- Obstetric complications present and/or anticipated that could, in the opinion of the investigator, impact the study objectives
- Pregnancy conceived via donor oocyte (egg donation)
- Known plans to move outside the pre-selected recruitment census tracts before the infant reaches 4 months of age
- Intent to transfer infant custody (e.g., via adoption or foster placement) within 4 months of birth
- Past or current medical problems that are not listed above, which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the participant's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Infants who meet any of the following criteria at the Birth Visit are not eligible for further study participation:
- Delivery before 36 weeks gestation
- Diagnosed at birth with any medical condition which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the family's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Pregnant females 18 years and older and their infants upon delivery
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Gene expression of nasal swab RNA samples
Lasso di tempo: 4 months
|
Gene expression will be measured by whole transcriptome RNA sequencing |
4 months
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: James E Gern, MD, University of Wisconsin, Madison
- Cattedra di studio: Jo L Wilson, MD, University of Wisconsin, Madison
- Direttore dello studio: Daniel Jackson, MD, University of Wisconsin, Madison
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- DAIT CAUSE-05
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Immunonology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Periodo di condivisione IPD
On average, within 24 months after database lock for the trial.
Criteri di accesso alla condivisione IPD
Open access
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .